Brii Biosciences has stepped in to ease VBI Vaccines’ money problems. The Chinese biotech is handing VBI $15 million to strike a deal that will give it global license to a hepatitis B program—and an ...
Brii Biosciences is putting all its chips on hepatitis B, hoping that potential partners will show an interest in picking up the remainder of a wide-ranging pipeline that includes HIV, lung disease ...
Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet ...
The Breakthrough Therapy Designation for BRII-877 (tobevibart) was supported by Phase 1 and 2 studies conducted by Vir Biotechnology ("Vir", Nasdaq: VIR) and Brii Bio. As of September 2023, more than ...
DURHAM, N.C. & BEIJING--(BUSINESS WIRE)--Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public ...
DURHAM, N.C. & BEIJING--(BUSINESS WIRE)--Brii Biosciences (“Brii Bio”), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public ...
RESEARCH TRIANGLE PARK – Durham-based Brii Biosciences will net some $24 million up front and also secured future royalty payments in a deal involving the sale of its share in a biotech that’s being ...
But the brief commercial run of BRII-196/198, a long-acting combination of amubarvimab and romlusevimab, is over, the company said on Friday. Brii will stop manufacturing the cocktail in China and has ...
(RTTNews) - Brii Biosciences Limited said that it reached agreements with VBI Vaccines Inc. (VBIV), ensuring expansion and control of future clinical and commercial supplies of BRII-179, a late-stage ...
Editor’s note: LimeLight is a new feature from WRAL TechWire offering another means of publishing noteworthy news. Be sure to check out more LimeLight worthy news at this link. Mr. Stout brings with ...
Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy With effective cost control measures in place, Brii Bio remains well-capitalized, maintaining a cash position of ...
Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy The article, titled "Elebsiran and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback